Current reports
8-K
Chromocell Issues Letter to Stockholders from Chief Executive Officer
9 Apr 24
8-K
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
21 Mar 24
8-K
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
18 Mar 24
8-K
Regulation FD Disclosure
13 Mar 24
8-K
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
22 Feb 24
Registration and prospectus
POS EX
Additional exhibits for listing
16 Apr 24
424B3
Prospectus supplement
16 Apr 24
424B3
Prospectus supplement
16 Apr 24
S-8
Registration of securities for employees
12 Apr 24
424B4
Prospectus supplement with pricing info
20 Feb 24
424B4
Prospectus supplement with pricing info
20 Feb 24
POS EX
Additional exhibits for listing
15 Feb 24
8-A12B
Registration of securities on exchange
15 Feb 24
S-1/A
IPO registration (amended)
14 Feb 24
FWP
Free writing prospectus
12 Feb 24
Proxies
No filings
Other
SEC STAFF
SEC staff action: Order
20 Feb 24
CERT
Certification of approval for exchange listing
15 Feb 24
EFFECT
Notice of effectiveness
15 Feb 24
CORRESP
Correspondence with SEC
12 Feb 24
CORRESP
Correspondence with SEC
12 Feb 24
CORRESP
Correspondence with SEC
30 Jan 24
UPLOAD
Letter from SEC
25 Jan 24
SEC STAFF
SEC staff action: Order
23 Jan 24
Ownership
4/A
Ezra M Friedberg
12 Mar 24
SC 13G
Boswell Prayer Ltd.
4 Mar 24
SC 13G
Benuvia Operations, LLC
1 Mar 24
SC 13G
Aperture Healthcare Ventures Ltd.
1 Mar 24
SC 13G
AME Equities LLC
1 Mar 24
SC 13G
Motif Pharmaceuticals Ltd.
1 Mar 24
SC 13G
3i, LP
1 Mar 24
SC 13D
Friedberg Ezra M
26 Feb 24
4
Knuettel Francis II
23 Feb 24
4
Todd C Davis
23 Feb 24